nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—CYP1A1—Clobetasol propionate—psoriasis	0.0823	0.126	CbGbCtD
Gefitinib—CYP1A1—Methoxsalen—psoriasis	0.0432	0.0664	CbGbCtD
Gefitinib—ALB—Acitretin—psoriasis	0.0396	0.0608	CbGbCtD
Gefitinib—CYP3A5—Beclomethasone—psoriasis	0.0374	0.0575	CbGbCtD
Gefitinib—CYP1A1—Cholecalciferol—psoriasis	0.0286	0.044	CbGbCtD
Gefitinib—ABCG2—Mycophenolate mofetil—psoriasis	0.0269	0.0413	CbGbCtD
Gefitinib—ABCG2—Hydrocortisone—psoriasis	0.0216	0.0332	CbGbCtD
Gefitinib—ABCG2—Cyclosporine—psoriasis	0.0204	0.0313	CbGbCtD
Gefitinib—ALB—Mycophenolate mofetil—psoriasis	0.0185	0.0285	CbGbCtD
Gefitinib—CYP2D6—Hydroxyurea—psoriasis	0.0174	0.0267	CbGbCtD
Gefitinib—CYP3A5—Mycophenolate mofetil—psoriasis	0.0149	0.0229	CbGbCtD
Gefitinib—ALB—Prednisone—psoriasis	0.0148	0.0228	CbGbCtD
Gefitinib—CYP2C19—Cholecalciferol—psoriasis	0.0139	0.0213	CbGbCtD
Gefitinib—ABCG2—Dexamethasone—psoriasis	0.0134	0.0206	CbGbCtD
Gefitinib—CYP3A4—Calcitriol—psoriasis	0.013	0.02	CbGbCtD
Gefitinib—CYP1A1—Dexamethasone—psoriasis	0.0124	0.019	CbGbCtD
Gefitinib—CYP3A5—Hydrocortisone—psoriasis	0.012	0.0184	CbGbCtD
Gefitinib—CYP2C9—Cholecalciferol—psoriasis	0.0115	0.0177	CbGbCtD
Gefitinib—CYP3A5—Cyclosporine—psoriasis	0.0113	0.0173	CbGbCtD
Gefitinib—ABCG2—Methotrexate—psoriasis	0.0108	0.0166	CbGbCtD
Gefitinib—CYP2D6—Cholecalciferol—psoriasis	0.0105	0.0162	CbGbCtD
Gefitinib—CYP3A4—Methoxsalen—psoriasis	0.0101	0.0155	CbGbCtD
Gefitinib—ABCB1—Mycophenolate mofetil—psoriasis	0.0097	0.0149	CbGbCtD
Gefitinib—CYP2C19—Prednisone—psoriasis	0.00961	0.0148	CbGbCtD
Gefitinib—CYP2C19—Cyclosporine—psoriasis	0.00911	0.014	CbGbCtD
Gefitinib—ABCB1—Betamethasone—psoriasis	0.00832	0.0128	CbGbCtD
Gefitinib—ABCB1—Prednisolone—psoriasis	0.00821	0.0126	CbGbCtD
Gefitinib—ABCB1—Hydrocortisone—psoriasis	0.00778	0.012	CbGbCtD
Gefitinib—ABCB1—Prednisone—psoriasis	0.00775	0.0119	CbGbCtD
Gefitinib—CYP2C9—Cyclosporine—psoriasis	0.00757	0.0116	CbGbCtD
Gefitinib—CYP3A5—Dexamethasone—psoriasis	0.00744	0.0114	CbGbCtD
Gefitinib—ALB—Methotrexate—psoriasis	0.00743	0.0114	CbGbCtD
Gefitinib—ABCB1—Cyclosporine—psoriasis	0.00735	0.0113	CbGbCtD
Gefitinib—CYP2D6—Cyclosporine—psoriasis	0.00692	0.0106	CbGbCtD
Gefitinib—CYP3A4—Cholecalciferol—psoriasis	0.0067	0.0103	CbGbCtD
Gefitinib—CYP2C19—Dexamethasone—psoriasis	0.006	0.00921	CbGbCtD
Gefitinib—CYP3A4—Triamcinolone—psoriasis	0.00581	0.00893	CbGbCtD
Gefitinib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00581	0.00893	CbGbCtD
Gefitinib—CYP2C9—Dexamethasone—psoriasis	0.00499	0.00766	CbGbCtD
Gefitinib—CYP3A4—Betamethasone—psoriasis	0.00498	0.00766	CbGbCtD
Gefitinib—CYP3A4—Prednisolone—psoriasis	0.00492	0.00756	CbGbCtD
Gefitinib—ABCB1—Dexamethasone—psoriasis	0.00484	0.00743	CbGbCtD
Gefitinib—CYP3A4—Hydrocortisone—psoriasis	0.00466	0.00716	CbGbCtD
Gefitinib—CYP3A4—Prednisone—psoriasis	0.00464	0.00714	CbGbCtD
Gefitinib—CYP2D6—Dexamethasone—psoriasis	0.00456	0.00701	CbGbCtD
Gefitinib—CYP3A4—Cyclosporine—psoriasis	0.0044	0.00676	CbGbCtD
Gefitinib—ABCB1—Methotrexate—psoriasis	0.00389	0.00597	CbGbCtD
Gefitinib—CYP3A4—Dexamethasone—psoriasis	0.0029	0.00445	CbGbCtD
Gefitinib—Vandetanib—VEGFA—psoriasis	0.000762	1	CrCbGaD
Gefitinib—ORM1—vertebral column—psoriasis	0.00052	0.225	CbGeAlD
Gefitinib—CSNK1E—Dexamethasone—Clobetasol propionate—psoriasis	0.000373	0.0772	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Clobetasol propionate—psoriasis	0.000373	0.0772	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Beclomethasone—psoriasis	0.000299	0.0619	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Fluocinonide—psoriasis	0.000299	0.0619	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Beclomethasone—psoriasis	0.000299	0.0619	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Fluocinonide—psoriasis	0.000299	0.0619	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Fluocinolone Acetonide—psoriasis	0.00029	0.0601	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Fluocinolone Acetonide—psoriasis	0.00029	0.0601	CbGdCrCtD
Gefitinib—SBK1—tendon—psoriasis	0.000252	0.109	CbGeAlD
Gefitinib—CSNK1E—Danazol—Hydrocortisone—psoriasis	0.00023	0.0476	CbGdCrCtD
Gefitinib—CHEK2—tendon—psoriasis	0.000219	0.0947	CbGeAlD
Gefitinib—CSNK1E—Danazol—Prednisone—psoriasis	0.000198	0.041	CbGdCrCtD
Gefitinib—CSNK1E—skin of body—psoriasis	0.000183	0.0789	CbGeAlD
Gefitinib—CYP1A1—skin epidermis—psoriasis	0.000181	0.0784	CbGeAlD
Gefitinib—ERBB3—skin of body—psoriasis	0.000176	0.0761	CbGeAlD
Gefitinib—CSNK1E—Dexamethasone—Hydrocortisone—psoriasis	0.000147	0.0304	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Hydrocortisone—psoriasis	0.000147	0.0304	CbGdCrCtD
Gefitinib—CHEK2—Testosterone Propionate—Hydrocortisone—psoriasis	0.000141	0.0293	CbGdCrCtD
Gefitinib—CSNK1E—tendon—psoriasis	0.000139	0.0601	CbGeAlD
Gefitinib—Toxic epidermal necrolysis—Methotrexate—psoriasis	0.000138	0.000644	CcSEcCtD
Gefitinib—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000138	0.000643	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000138	0.000642	CcSEcCtD
Gefitinib—Diarrhoea—Hydroxyurea—psoriasis	0.000138	0.000642	CcSEcCtD
Gefitinib—Malaise—Prednisolone—psoriasis	0.000137	0.000639	CcSEcCtD
Gefitinib—IRAK4—tendon—psoriasis	0.000137	0.0591	CbGeAlD
Gefitinib—Eye disorder—Betamethasone—psoriasis	0.000136	0.000635	CcSEcCtD
Gefitinib—Eye disorder—Dexamethasone—psoriasis	0.000136	0.000635	CcSEcCtD
Gefitinib—CSNK1E—Dexamethasone—Betamethasone—psoriasis	0.000136	0.0282	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Dexamethasone—psoriasis	0.000136	0.0282	CbGdCrCtD
Gefitinib—Dry mouth—Mycophenolate mofetil—psoriasis	0.000136	0.000633	CcSEcCtD
Gefitinib—Angioedema—Hydrocortisone—psoriasis	0.000136	0.000633	CcSEcCtD
Gefitinib—Infection—Cyclosporine—psoriasis	0.000136	0.000632	CcSEcCtD
Gefitinib—Malaise—Hydrocortisone—psoriasis	0.000134	0.000624	CcSEcCtD
Gefitinib—Nervous system disorder—Cyclosporine—psoriasis	0.000134	0.000623	CcSEcCtD
Gefitinib—Thrombocytopenia—Cyclosporine—psoriasis	0.000134	0.000622	CcSEcCtD
Gefitinib—Abdominal pain—Mycophenolic acid—psoriasis	0.000133	0.000621	CcSEcCtD
Gefitinib—Body temperature increased—Mycophenolic acid—psoriasis	0.000133	0.000621	CcSEcCtD
Gefitinib—CSNK1E—Dexamethasone—Triamcinolone—psoriasis	0.000133	0.0275	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Triamcinolone—psoriasis	0.000133	0.0275	CbGdCrCtD
Gefitinib—Skin disorder—Cyclosporine—psoriasis	0.000133	0.000618	CcSEcCtD
Gefitinib—Angiopathy—Betamethasone—psoriasis	0.000132	0.000616	CcSEcCtD
Gefitinib—Angiopathy—Dexamethasone—psoriasis	0.000132	0.000616	CcSEcCtD
Gefitinib—Infection—Mycophenolate mofetil—psoriasis	0.000132	0.000616	CcSEcCtD
Gefitinib—Shock—Mycophenolate mofetil—psoriasis	0.000131	0.00061	CcSEcCtD
Gefitinib—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000131	0.000608	CcSEcCtD
Gefitinib—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.00013	0.000607	CcSEcCtD
Gefitinib—Arrhythmia—Betamethasone—psoriasis	0.00013	0.000607	CcSEcCtD
Gefitinib—Arrhythmia—Dexamethasone—psoriasis	0.00013	0.000607	CcSEcCtD
Gefitinib—Anorexia—Cyclosporine—psoriasis	0.00013	0.000606	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—psoriasis	0.00013	0.000606	CcSEcCtD
Gefitinib—Skin disorder—Mycophenolate mofetil—psoriasis	0.000129	0.000602	CcSEcCtD
Gefitinib—Alopecia—Dexamethasone—psoriasis	0.000129	0.0006	CcSEcCtD
Gefitinib—Alopecia—Betamethasone—psoriasis	0.000129	0.0006	CcSEcCtD
Gefitinib—Vomiting—Hydroxyurea—psoriasis	0.000128	0.000597	CcSEcCtD
Gefitinib—Angioedema—Triamcinolone—psoriasis	0.000128	0.000596	CcSEcCtD
Gefitinib—Haemoglobin—Prednisone—psoriasis	0.000128	0.000595	CcSEcCtD
Gefitinib—MKNK2—tendon—psoriasis	0.000128	0.0551	CbGeAlD
Gefitinib—IRAK1—tendon—psoriasis	0.000128	0.0551	CbGeAlD
Gefitinib—Haemorrhage—Prednisone—psoriasis	0.000127	0.000592	CcSEcCtD
Gefitinib—Rash—Hydroxyurea—psoriasis	0.000127	0.000592	CcSEcCtD
Gefitinib—Anorexia—Mycophenolate mofetil—psoriasis	0.000127	0.000591	CcSEcCtD
Gefitinib—Dermatitis—Hydroxyurea—psoriasis	0.000127	0.000591	CcSEcCtD
Gefitinib—Malaise—Triamcinolone—psoriasis	0.000126	0.000588	CcSEcCtD
Gefitinib—CSNK1E—Betamethasone—Prednisone—psoriasis	0.000126	0.0261	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisone—psoriasis	0.000126	0.0261	CbGdCrCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000126	0.000585	CcSEcCtD
Gefitinib—Hypotension—Mycophenolate mofetil—psoriasis	0.000124	0.00058	CcSEcCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisolone—psoriasis	0.000123	0.0255	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Prednisolone—psoriasis	0.000123	0.0255	CbGdCrCtD
Gefitinib—Shock—Prednisolone—psoriasis	0.000122	0.000569	CcSEcCtD
Gefitinib—Cough—Triamcinolone—psoriasis	0.000122	0.000569	CcSEcCtD
Gefitinib—Dyspnoea—Cyclosporine—psoriasis	0.000122	0.000567	CcSEcCtD
Gefitinib—Asthenia—Mycophenolic acid—psoriasis	0.000121	0.000564	CcSEcCtD
Gefitinib—Infection—Hydrocortisone—psoriasis	0.000121	0.000561	CcSEcCtD
Gefitinib—Nausea—Hydroxyurea—psoriasis	0.00012	0.000557	CcSEcCtD
Gefitinib—Pruritus—Mycophenolic acid—psoriasis	0.000119	0.000556	CcSEcCtD
Gefitinib—Shock—Hydrocortisone—psoriasis	0.000119	0.000556	CcSEcCtD
Gefitinib—Nervous system disorder—Hydrocortisone—psoriasis	0.000119	0.000554	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—psoriasis	0.000119	0.000554	CcSEcCtD
Gefitinib—Eye disorder—Prednisone—psoriasis	0.000119	0.000553	CcSEcCtD
Gefitinib—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000119	0.000553	CcSEcCtD
Gefitinib—Decreased appetite—Cyclosporine—psoriasis	0.000119	0.000553	CcSEcCtD
Gefitinib—Infestation—Methotrexate—psoriasis	0.000118	0.000551	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—psoriasis	0.000118	0.000551	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000118	0.000549	CcSEcCtD
Gefitinib—Skin disorder—Hydrocortisone—psoriasis	0.000118	0.000549	CcSEcCtD
Gefitinib—Fatigue—Cyclosporine—psoriasis	0.000118	0.000548	CcSEcCtD
Gefitinib—CHEK2—Danazol—Hydrocortisone—psoriasis	0.000118	0.0243	CbGdCrCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000117	0.000546	CcSEcCtD
Gefitinib—Pain—Cyclosporine—psoriasis	0.000117	0.000544	CcSEcCtD
Gefitinib—Constipation—Cyclosporine—psoriasis	0.000117	0.000544	CcSEcCtD
Gefitinib—Dry mouth—Triamcinolone—psoriasis	0.000117	0.000543	CcSEcCtD
Gefitinib—Angioedema—Betamethasone—psoriasis	0.000116	0.00054	CcSEcCtD
Gefitinib—Angioedema—Dexamethasone—psoriasis	0.000116	0.00054	CcSEcCtD
Gefitinib—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000116	0.000539	CcSEcCtD
Gefitinib—Anorexia—Hydrocortisone—psoriasis	0.000116	0.000539	CcSEcCtD
Gefitinib—Diarrhoea—Mycophenolic acid—psoriasis	0.000115	0.000538	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—psoriasis	0.000115	0.000537	CcSEcCtD
Gefitinib—Angiopathy—Prednisone—psoriasis	0.000115	0.000537	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—psoriasis	0.000115	0.000535	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000115	0.000535	CcSEcCtD
Gefitinib—Malaise—Betamethasone—psoriasis	0.000115	0.000533	CcSEcCtD
Gefitinib—Malaise—Dexamethasone—psoriasis	0.000115	0.000533	CcSEcCtD
Gefitinib—Pain—Mycophenolate mofetil—psoriasis	0.000114	0.00053	CcSEcCtD
Gefitinib—Constipation—Mycophenolate mofetil—psoriasis	0.000114	0.00053	CcSEcCtD
Gefitinib—Arrhythmia—Prednisone—psoriasis	0.000114	0.000529	CcSEcCtD
Gefitinib—Infection—Triamcinolone—psoriasis	0.000114	0.000529	CcSEcCtD
Gefitinib—Hypotension—Hydrocortisone—psoriasis	0.000113	0.000528	CcSEcCtD
Gefitinib—Haematuria—Methotrexate—psoriasis	0.000113	0.000525	CcSEcCtD
Gefitinib—Shock—Triamcinolone—psoriasis	0.000112	0.000523	CcSEcCtD
Gefitinib—Alopecia—Prednisone—psoriasis	0.000112	0.000523	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—psoriasis	0.000112	0.000521	CcSEcCtD
Gefitinib—Gastrointestinal pain—Cyclosporine—psoriasis	0.000112	0.00052	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—psoriasis	0.000112	0.00052	CcSEcCtD
Gefitinib—Malnutrition—Prednisone—psoriasis	0.000111	0.000515	CcSEcCtD
Gefitinib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000109	0.000507	CcSEcCtD
Gefitinib—Urticaria—Cyclosporine—psoriasis	0.000108	0.000505	CcSEcCtD
Gefitinib—Abdominal pain—Cyclosporine—psoriasis	0.000108	0.000503	CcSEcCtD
Gefitinib—Body temperature increased—Cyclosporine—psoriasis	0.000108	0.000503	CcSEcCtD
Gefitinib—Vomiting—Mycophenolic acid—psoriasis	0.000107	0.0005	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—psoriasis	0.000107	0.000497	CcSEcCtD
Gefitinib—Rash—Mycophenolic acid—psoriasis	0.000106	0.000495	CcSEcCtD
Gefitinib—Dermatitis—Mycophenolic acid—psoriasis	0.000106	0.000495	CcSEcCtD
Gefitinib—Pain—Prednisolone—psoriasis	0.000106	0.000495	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—psoriasis	0.000106	0.000495	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—psoriasis	0.000106	0.000495	CcSEcCtD
Gefitinib—CHEK2—Norethindrone—Hydrocortisone—psoriasis	0.000106	0.0219	CbGdCrCtD
Gefitinib—Urticaria—Mycophenolate mofetil—psoriasis	0.000106	0.000493	CcSEcCtD
Gefitinib—Decreased appetite—Hydrocortisone—psoriasis	0.000105	0.000491	CcSEcCtD
Gefitinib—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000105	0.00049	CcSEcCtD
Gefitinib—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000105	0.00049	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—psoriasis	0.000105	0.000488	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000105	0.000488	CcSEcCtD
Gefitinib—Fatigue—Hydrocortisone—psoriasis	0.000105	0.000487	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—psoriasis	0.000104	0.000485	CcSEcCtD
Gefitinib—Pain—Hydrocortisone—psoriasis	0.000104	0.000483	CcSEcCtD
Gefitinib—STK10—tendon—psoriasis	0.000104	0.0448	CbGeAlD
Gefitinib—Infection—Betamethasone—psoriasis	0.000103	0.00048	CcSEcCtD
Gefitinib—Infection—Dexamethasone—psoriasis	0.000103	0.00048	CcSEcCtD
Gefitinib—Anaemia—Prednisone—psoriasis	0.000102	0.000476	CcSEcCtD
Gefitinib—Shock—Dexamethasone—psoriasis	0.000102	0.000475	CcSEcCtD
Gefitinib—Shock—Betamethasone—psoriasis	0.000102	0.000475	CcSEcCtD
Gefitinib—Dyspnoea—Triamcinolone—psoriasis	0.000102	0.000474	CcSEcCtD
Gefitinib—Nervous system disorder—Dexamethasone—psoriasis	0.000102	0.000473	CcSEcCtD
Gefitinib—Nervous system disorder—Betamethasone—psoriasis	0.000102	0.000473	CcSEcCtD
Gefitinib—Thrombocytopenia—Dexamethasone—psoriasis	0.000102	0.000473	CcSEcCtD
Gefitinib—Thrombocytopenia—Betamethasone—psoriasis	0.000102	0.000473	CcSEcCtD
Gefitinib—CHEK2—Danazol—Prednisone—psoriasis	0.000101	0.021	CbGdCrCtD
Gefitinib—Angioedema—Prednisone—psoriasis	0.000101	0.000471	CcSEcCtD
Gefitinib—Hypersensitivity—Cyclosporine—psoriasis	0.000101	0.000468	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—psoriasis	0.0001	0.000468	CcSEcCtD
Gefitinib—Nausea—Mycophenolic acid—psoriasis	0.0001	0.000467	CcSEcCtD
Gefitinib—Malaise—Prednisone—psoriasis	9.98e-05	0.000465	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—psoriasis	9.93e-05	0.000462	CcSEcCtD
Gefitinib—Gastrointestinal pain—Hydrocortisone—psoriasis	9.92e-05	0.000462	CcSEcCtD
Gefitinib—Anorexia—Dexamethasone—psoriasis	9.88e-05	0.00046	CcSEcCtD
Gefitinib—Anorexia—Betamethasone—psoriasis	9.88e-05	0.00046	CcSEcCtD
Gefitinib—Urticaria—Prednisolone—psoriasis	9.87e-05	0.00046	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—psoriasis	9.86e-05	0.000459	CcSEcCtD
Gefitinib—Fatigue—Triamcinolone—psoriasis	9.85e-05	0.000459	CcSEcCtD
Gefitinib—Hypersensitivity—Mycophenolate mofetil—psoriasis	9.81e-05	0.000457	CcSEcCtD
Gefitinib—Asthenia—Cyclosporine—psoriasis	9.8e-05	0.000456	CcSEcCtD
Gefitinib—Pain—Triamcinolone—psoriasis	9.77e-05	0.000455	CcSEcCtD
Gefitinib—Hypotension—Dexamethasone—psoriasis	9.69e-05	0.000451	CcSEcCtD
Gefitinib—Hypotension—Betamethasone—psoriasis	9.69e-05	0.000451	CcSEcCtD
Gefitinib—Pruritus—Cyclosporine—psoriasis	9.66e-05	0.00045	CcSEcCtD
Gefitinib—Urticaria—Hydrocortisone—psoriasis	9.64e-05	0.000449	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—psoriasis	9.64e-05	0.000449	CcSEcCtD
Gefitinib—Abdominal pain—Hydrocortisone—psoriasis	9.59e-05	0.000447	CcSEcCtD
Gefitinib—Body temperature increased—Hydrocortisone—psoriasis	9.59e-05	0.000447	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—psoriasis	9.57e-05	0.000446	CcSEcCtD
Gefitinib—Asthenia—Mycophenolate mofetil—psoriasis	9.56e-05	0.000445	CcSEcCtD
Gefitinib—Pruritus—Mycophenolate mofetil—psoriasis	9.42e-05	0.000439	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—psoriasis	9.39e-05	0.000437	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	9.35e-05	0.000436	CcSEcCtD
Gefitinib—Diarrhoea—Cyclosporine—psoriasis	9.34e-05	0.000435	CcSEcCtD
Gefitinib—MAP2K5—tendon—psoriasis	9.26e-05	0.04	CbGeAlD
Gefitinib—Malnutrition—Methotrexate—psoriasis	9.25e-05	0.00043	CcSEcCtD
Gefitinib—Hypersensitivity—Prednisolone—psoriasis	9.16e-05	0.000426	CcSEcCtD
Gefitinib—Diarrhoea—Mycophenolate mofetil—psoriasis	9.11e-05	0.000424	CcSEcCtD
Gefitinib—Urticaria—Triamcinolone—psoriasis	9.08e-05	0.000423	CcSEcCtD
Gefitinib—Body temperature increased—Triamcinolone—psoriasis	9.03e-05	0.000421	CcSEcCtD
Gefitinib—Decreased appetite—Dexamethasone—psoriasis	9.01e-05	0.00042	CcSEcCtD
Gefitinib—Decreased appetite—Betamethasone—psoriasis	9.01e-05	0.00042	CcSEcCtD
Gefitinib—Infection—Prednisone—psoriasis	8.97e-05	0.000418	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Dexamethasone—psoriasis	8.95e-05	0.000417	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Betamethasone—psoriasis	8.95e-05	0.000417	CcSEcCtD
Gefitinib—Hypersensitivity—Hydrocortisone—psoriasis	8.94e-05	0.000416	CcSEcCtD
Gefitinib—Fatigue—Dexamethasone—psoriasis	8.94e-05	0.000416	CcSEcCtD
Gefitinib—Fatigue—Betamethasone—psoriasis	8.94e-05	0.000416	CcSEcCtD
Gefitinib—Shock—Prednisone—psoriasis	8.88e-05	0.000414	CcSEcCtD
Gefitinib—Pain—Betamethasone—psoriasis	8.87e-05	0.000413	CcSEcCtD
Gefitinib—Pain—Dexamethasone—psoriasis	8.87e-05	0.000413	CcSEcCtD
Gefitinib—Nervous system disorder—Prednisone—psoriasis	8.86e-05	0.000412	CcSEcCtD
Gefitinib—Skin disorder—Prednisone—psoriasis	8.77e-05	0.000408	CcSEcCtD
Gefitinib—Asthenia—Hydrocortisone—psoriasis	8.71e-05	0.000405	CcSEcCtD
Gefitinib—Vomiting—Cyclosporine—psoriasis	8.68e-05	0.000404	CcSEcCtD
Gefitinib—Rash—Cyclosporine—psoriasis	8.61e-05	0.000401	CcSEcCtD
Gefitinib—Anorexia—Prednisone—psoriasis	8.61e-05	0.000401	CcSEcCtD
Gefitinib—Dermatitis—Cyclosporine—psoriasis	8.6e-05	0.0004	CcSEcCtD
Gefitinib—Pruritus—Hydrocortisone—psoriasis	8.59e-05	0.0004	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—psoriasis	8.55e-05	0.000398	CcSEcCtD
Gefitinib—Gastrointestinal pain—Betamethasone—psoriasis	8.48e-05	0.000395	CcSEcCtD
Gefitinib—Gastrointestinal pain—Dexamethasone—psoriasis	8.48e-05	0.000395	CcSEcCtD
Gefitinib—Vomiting—Mycophenolate mofetil—psoriasis	8.47e-05	0.000394	CcSEcCtD
Gefitinib—CHEK2—Levonorgestrel—Hydrocortisone—psoriasis	8.42e-05	0.0175	CbGdCrCtD
Gefitinib—Hypersensitivity—Triamcinolone—psoriasis	8.42e-05	0.000392	CcSEcCtD
Gefitinib—Rash—Mycophenolate mofetil—psoriasis	8.4e-05	0.000391	CcSEcCtD
Gefitinib—Dermatitis—Mycophenolate mofetil—psoriasis	8.39e-05	0.000391	CcSEcCtD
Gefitinib—Malaise—Methotrexate—psoriasis	8.34e-05	0.000388	CcSEcCtD
Gefitinib—Diarrhoea—Hydrocortisone—psoriasis	8.3e-05	0.000387	CcSEcCtD
Gefitinib—Urticaria—Dexamethasone—psoriasis	8.24e-05	0.000383	CcSEcCtD
Gefitinib—Urticaria—Betamethasone—psoriasis	8.24e-05	0.000383	CcSEcCtD
Gefitinib—Asthenia—Triamcinolone—psoriasis	8.2e-05	0.000382	CcSEcCtD
Gefitinib—Body temperature increased—Dexamethasone—psoriasis	8.2e-05	0.000382	CcSEcCtD
Gefitinib—Abdominal pain—Dexamethasone—psoriasis	8.2e-05	0.000382	CcSEcCtD
Gefitinib—Abdominal pain—Betamethasone—psoriasis	8.2e-05	0.000382	CcSEcCtD
Gefitinib—Body temperature increased—Betamethasone—psoriasis	8.2e-05	0.000382	CcSEcCtD
Gefitinib—Nausea—Cyclosporine—psoriasis	8.11e-05	0.000378	CcSEcCtD
Gefitinib—Pruritus—Triamcinolone—psoriasis	8.08e-05	0.000376	CcSEcCtD
Gefitinib—Cough—Methotrexate—psoriasis	8.07e-05	0.000376	CcSEcCtD
Gefitinib—Nausea—Mycophenolate mofetil—psoriasis	7.91e-05	0.000368	CcSEcCtD
Gefitinib—Decreased appetite—Prednisone—psoriasis	7.85e-05	0.000365	CcSEcCtD
Gefitinib—Rash—Prednisolone—psoriasis	7.83e-05	0.000365	CcSEcCtD
Gefitinib—Dermatitis—Prednisolone—psoriasis	7.83e-05	0.000364	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	7.82e-05	0.000364	CcSEcCtD
Gefitinib—Fatigue—Prednisone—psoriasis	7.79e-05	0.000362	CcSEcCtD
Gefitinib—Constipation—Prednisone—psoriasis	7.72e-05	0.000359	CcSEcCtD
Gefitinib—Vomiting—Hydrocortisone—psoriasis	7.72e-05	0.000359	CcSEcCtD
Gefitinib—Rash—Hydrocortisone—psoriasis	7.65e-05	0.000356	CcSEcCtD
Gefitinib—Dermatitis—Hydrocortisone—psoriasis	7.64e-05	0.000356	CcSEcCtD
Gefitinib—Infection—Methotrexate—psoriasis	7.5e-05	0.000349	CcSEcCtD
Gefitinib—Asthenia—Betamethasone—psoriasis	7.44e-05	0.000346	CcSEcCtD
Gefitinib—Asthenia—Dexamethasone—psoriasis	7.44e-05	0.000346	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—psoriasis	7.4e-05	0.000345	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—psoriasis	7.39e-05	0.000344	CcSEcCtD
Gefitinib—Gastrointestinal pain—Prednisone—psoriasis	7.38e-05	0.000344	CcSEcCtD
Gefitinib—Nausea—Prednisolone—psoriasis	7.38e-05	0.000344	CcSEcCtD
Gefitinib—Pruritus—Betamethasone—psoriasis	7.34e-05	0.000342	CcSEcCtD
Gefitinib—Pruritus—Dexamethasone—psoriasis	7.34e-05	0.000342	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—psoriasis	7.33e-05	0.000341	CcSEcCtD
Gefitinib—Vomiting—Triamcinolone—psoriasis	7.27e-05	0.000338	CcSEcCtD
Gefitinib—Nausea—Hydrocortisone—psoriasis	7.21e-05	0.000336	CcSEcCtD
Gefitinib—Rash—Triamcinolone—psoriasis	7.21e-05	0.000335	CcSEcCtD
Gefitinib—Dermatitis—Triamcinolone—psoriasis	7.2e-05	0.000335	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—psoriasis	7.19e-05	0.000335	CcSEcCtD
Gefitinib—Urticaria—Prednisone—psoriasis	7.17e-05	0.000334	CcSEcCtD
Gefitinib—Body temperature increased—Prednisone—psoriasis	7.14e-05	0.000332	CcSEcCtD
Gefitinib—Abdominal pain—Prednisone—psoriasis	7.14e-05	0.000332	CcSEcCtD
Gefitinib—Diarrhoea—Betamethasone—psoriasis	7.09e-05	0.00033	CcSEcCtD
Gefitinib—Diarrhoea—Dexamethasone—psoriasis	7.09e-05	0.00033	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—psoriasis	7.05e-05	0.000328	CcSEcCtD
Gefitinib—Nausea—Triamcinolone—psoriasis	6.79e-05	0.000316	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—psoriasis	6.73e-05	0.000313	CcSEcCtD
Gefitinib—Hypersensitivity—Prednisone—psoriasis	6.65e-05	0.00031	CcSEcCtD
Gefitinib—Vomiting—Betamethasone—psoriasis	6.59e-05	0.000307	CcSEcCtD
Gefitinib—Vomiting—Dexamethasone—psoriasis	6.59e-05	0.000307	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—psoriasis	6.56e-05	0.000305	CcSEcCtD
Gefitinib—Rash—Betamethasone—psoriasis	6.54e-05	0.000304	CcSEcCtD
Gefitinib—Rash—Dexamethasone—psoriasis	6.54e-05	0.000304	CcSEcCtD
Gefitinib—Dermatitis—Betamethasone—psoriasis	6.53e-05	0.000304	CcSEcCtD
Gefitinib—Dermatitis—Dexamethasone—psoriasis	6.53e-05	0.000304	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—psoriasis	6.52e-05	0.000303	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—psoriasis	6.51e-05	0.000303	CcSEcCtD
Gefitinib—Asthenia—Prednisone—psoriasis	6.48e-05	0.000302	CcSEcCtD
Gefitinib—Pain—Methotrexate—psoriasis	6.45e-05	0.0003	CcSEcCtD
Gefitinib—Pruritus—Prednisone—psoriasis	6.39e-05	0.000297	CcSEcCtD
Gefitinib—Diarrhoea—Prednisone—psoriasis	6.18e-05	0.000288	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—psoriasis	6.17e-05	0.000287	CcSEcCtD
Gefitinib—Nausea—Dexamethasone—psoriasis	6.16e-05	0.000287	CcSEcCtD
Gefitinib—Nausea—Betamethasone—psoriasis	6.16e-05	0.000287	CcSEcCtD
Gefitinib—Urticaria—Methotrexate—psoriasis	6e-05	0.000279	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—psoriasis	5.97e-05	0.000278	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—psoriasis	5.97e-05	0.000278	CcSEcCtD
Gefitinib—Vomiting—Prednisone—psoriasis	5.74e-05	0.000267	CcSEcCtD
Gefitinib—Rash—Prednisone—psoriasis	5.69e-05	0.000265	CcSEcCtD
Gefitinib—Dermatitis—Prednisone—psoriasis	5.69e-05	0.000265	CcSEcCtD
Gefitinib—CYP1A1—skin of body—psoriasis	5.62e-05	0.0243	CbGeAlD
Gefitinib—Hypersensitivity—Methotrexate—psoriasis	5.56e-05	0.000259	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—psoriasis	5.41e-05	0.000252	CcSEcCtD
Gefitinib—Nausea—Prednisone—psoriasis	5.36e-05	0.00025	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—psoriasis	5.34e-05	0.000249	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—psoriasis	5.16e-05	0.00024	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—psoriasis	4.8e-05	0.000223	CcSEcCtD
Gefitinib—Rash—Methotrexate—psoriasis	4.76e-05	0.000222	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—psoriasis	4.75e-05	0.000221	CcSEcCtD
Gefitinib—Nausea—Methotrexate—psoriasis	4.48e-05	0.000209	CcSEcCtD
Gefitinib—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.51e-05	0.000198	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NFKBIA—psoriasis	2.51e-05	0.000198	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD8A—psoriasis	2.47e-05	0.000195	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—NFKB1—psoriasis	2.46e-05	0.000194	CbGpPWpGaD
Gefitinib—EGFR—Downstream signal transduction—IL6—psoriasis	2.44e-05	0.000193	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HLA-A—psoriasis	2.44e-05	0.000193	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CD4—psoriasis	2.43e-05	0.000192	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR—IL6—psoriasis	2.43e-05	0.000192	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-A—psoriasis	2.42e-05	0.000192	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB2—IL6—psoriasis	2.42e-05	0.000191	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—NFKB1—psoriasis	2.42e-05	0.000191	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-DRB1—psoriasis	2.41e-05	0.000191	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CRP—psoriasis	2.41e-05	0.00019	CbGpPWpGaD
Gefitinib—EGFR—DAP12 signaling—IL6—psoriasis	2.41e-05	0.00019	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.39e-05	0.000189	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—TP53—psoriasis	2.38e-05	0.000188	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-B—psoriasis	2.37e-05	0.000188	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—TYK2—psoriasis	2.36e-05	0.000187	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP2S1—psoriasis	2.35e-05	0.000186	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.35e-05	0.000186	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL6—psoriasis	2.35e-05	0.000186	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.33e-05	0.000184	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—PPARG—psoriasis	2.32e-05	0.000184	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—ICAM1—psoriasis	2.32e-05	0.000183	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—IL6—psoriasis	2.31e-05	0.000182	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—NFKBIA—psoriasis	2.3e-05	0.000182	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP2S1—psoriasis	2.3e-05	0.000182	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—IL6—psoriasis	2.28e-05	0.00018	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—TYK2—psoriasis	2.28e-05	0.00018	CbGpPWpGaD
Gefitinib—ERBB3—Disease—APOE—psoriasis	2.28e-05	0.00018	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—IL6—psoriasis	2.26e-05	0.000179	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	2.26e-05	0.000179	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—IL6—psoriasis	2.26e-05	0.000179	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—IL6—psoriasis	2.24e-05	0.000177	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SOCS1—psoriasis	2.24e-05	0.000177	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-E—psoriasis	2.23e-05	0.000176	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—IL6—psoriasis	2.22e-05	0.000176	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-DRB1—psoriasis	2.22e-05	0.000175	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—IL6—psoriasis	2.21e-05	0.000175	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IFNG—psoriasis	2.21e-05	0.000175	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—STAT3—psoriasis	2.21e-05	0.000175	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-A—psoriasis	2.2e-05	0.000174	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—NFKBIA—psoriasis	2.2e-05	0.000174	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL20—psoriasis	2.18e-05	0.000173	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—JUN—psoriasis	2.18e-05	0.000172	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP2S1—psoriasis	2.16e-05	0.000171	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SOCS1—psoriasis	2.16e-05	0.000171	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP2S1—psoriasis	2.14e-05	0.00017	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD4—psoriasis	2.14e-05	0.000169	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—ICAM1—psoriasis	2.13e-05	0.000168	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NOS2—psoriasis	2.12e-05	0.000168	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—NFKBIA—psoriasis	2.11e-05	0.000167	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CRP—psoriasis	2.1e-05	0.000166	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—NFKB1—psoriasis	2.1e-05	0.000166	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—LEP—psoriasis	2.09e-05	0.000165	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—APOE—psoriasis	2.09e-05	0.000165	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CARM1—psoriasis	2.07e-05	0.000164	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CD4—psoriasis	2.06e-05	0.000163	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TYK2—psoriasis	2.05e-05	0.000162	CbGpPWpGaD
Gefitinib—MKNK1—Disease—STAT3—psoriasis	2.05e-05	0.000162	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TYK2—psoriasis	2.04e-05	0.000161	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—VEGFA—psoriasis	2.02e-05	0.00016	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-DRB1—psoriasis	2.01e-05	0.000159	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	2.01e-05	0.000159	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—IL6—psoriasis	1.98e-05	0.000157	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NFKBIA—psoriasis	1.95e-05	0.000154	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.94e-05	0.000153	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—ICAM1—psoriasis	1.93e-05	0.000153	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NFKBIA—psoriasis	1.91e-05	0.000151	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—JUN—psoriasis	1.91e-05	0.000151	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—TYK2—psoriasis	1.88e-05	0.000149	CbGpPWpGaD
Gefitinib—EGFR—Immune System—SOCS1—psoriasis	1.86e-05	0.000147	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—NFKB1—psoriasis	1.84e-05	0.000145	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—TYK2—psoriasis	1.8e-05	0.000142	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SOCS1—psoriasis	1.8e-05	0.000142	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CXCL8—psoriasis	1.79e-05	0.000141	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.78e-05	0.000141	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IFNG—psoriasis	1.76e-05	0.000139	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TYK2—psoriasis	1.74e-05	0.000137	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.71e-05	0.000136	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD4—psoriasis	1.7e-05	0.000135	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NDUFA5—psoriasis	1.66e-05	0.000132	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—JUN—psoriasis	1.66e-05	0.000131	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—APOE—psoriasis	1.65e-05	0.000131	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—LEP—psoriasis	1.65e-05	0.000131	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—STAT3—psoriasis	1.65e-05	0.000131	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD8A—psoriasis	1.65e-05	0.00013	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CD4—psoriasis	1.63e-05	0.000129	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NFKB1—psoriasis	1.6e-05	0.000127	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TYK2—psoriasis	1.6e-05	0.000126	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—STAT3—psoriasis	1.6e-05	0.000126	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—APOE—psoriasis	1.59e-05	0.000126	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—LEP—psoriasis	1.59e-05	0.000126	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—NFKB1—psoriasis	1.59e-05	0.000126	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-B—psoriasis	1.59e-05	0.000126	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—IL6—psoriasis	1.58e-05	0.000125	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.58e-05	0.000125	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CD4—psoriasis	1.57e-05	0.000124	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—TYK2—psoriasis	1.57e-05	0.000124	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD4—psoriasis	1.56e-05	0.000124	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.56e-05	0.000123	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—IL6—psoriasis	1.54e-05	0.000122	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NFKBIA—psoriasis	1.54e-05	0.000122	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—JUN—psoriasis	1.52e-05	0.00012	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.51e-05	0.000119	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CARM1—psoriasis	1.49e-05	0.000117	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NFKBIA—psoriasis	1.49e-05	0.000117	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-A—psoriasis	1.47e-05	0.000116	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IFNG—psoriasis	1.47e-05	0.000116	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—NFKB1—psoriasis	1.47e-05	0.000116	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—JUN—psoriasis	1.46e-05	0.000115	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—VEGFA—psoriasis	1.45e-05	0.000115	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—VEGFA—psoriasis	1.44e-05	0.000114	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—STAT3—psoriasis	1.44e-05	0.000114	CbGpPWpGaD
Gefitinib—MKNK1—Disease—IL6—psoriasis	1.43e-05	0.000113	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—STAT3—psoriasis	1.43e-05	0.000113	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD4—psoriasis	1.42e-05	0.000112	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2S1—psoriasis	1.41e-05	0.000112	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NOS2—psoriasis	1.41e-05	0.000111	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CARM1—psoriasis	1.4e-05	0.000111	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CRP—psoriasis	1.4e-05	0.000111	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—NFKB1—psoriasis	1.4e-05	0.000111	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—IL6—psoriasis	1.4e-05	0.00011	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CXCL8—psoriasis	1.39e-05	0.00011	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.37e-05	0.000109	CbGpPWpGaD
Gefitinib—EGFR—Disease—HLA-A—psoriasis	1.36e-05	0.000107	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—NFKB1—psoriasis	1.35e-05	0.000106	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-DRB1—psoriasis	1.34e-05	0.000106	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.33e-05	0.000105	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—LEP—psoriasis	1.33e-05	0.000105	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—APOE—psoriasis	1.33e-05	0.000105	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—STAT3—psoriasis	1.32e-05	0.000104	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—IL6—psoriasis	1.32e-05	0.000104	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.31e-05	0.000104	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—JUN—psoriasis	1.29e-05	0.000102	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ICAM1—psoriasis	1.29e-05	0.000102	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CARM1—psoriasis	1.28e-05	0.000101	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NFKBIA—psoriasis	1.28e-05	0.000101	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CAT—psoriasis	1.28e-05	0.000101	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—JUN—psoriasis	1.27e-05	0.0001	CbGpPWpGaD
Gefitinib—EGFR—Disease—APOE—psoriasis	1.27e-05	0.0001	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TYK2—psoriasis	1.26e-05	9.98e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NFKB1—psoriasis	1.24e-05	9.84e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NFKBIA—psoriasis	1.24e-05	9.78e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TNF—psoriasis	1.23e-05	9.76e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.23e-05	9.75e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NFKB1—psoriasis	1.22e-05	9.66e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TYK2—psoriasis	1.22e-05	9.62e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—STAT3—psoriasis	1.22e-05	9.62e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SOCS1—psoriasis	1.2e-05	9.51e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.2e-05	9.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOS2—psoriasis	1.18e-05	9.34e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.18e-05	9.29e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL6—psoriasis	1.15e-05	9.13e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CARM1—psoriasis	1.15e-05	9.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—TYK2—psoriasis	1.15e-05	9.07e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VEGFA—psoriasis	1.13e-05	8.93e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.12e-05	8.89e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CARM1—psoriasis	1.12e-05	8.87e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—STAT3—psoriasis	1.12e-05	8.84e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—IL6—psoriasis	1.12e-05	8.82e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CXCL8—psoriasis	1.1e-05	8.69e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—psoriasis	1.1e-05	8.68e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—STAT3—psoriasis	1.1e-05	8.68e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.07e-05	8.49e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CXCL8—psoriasis	1.06e-05	8.38e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CARM1—psoriasis	1.06e-05	8.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—TYK2—psoriasis	1.05e-05	8.29e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CARM1—psoriasis	1.05e-05	8.28e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—JUN—psoriasis	1.02e-05	8.08e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TYK2—psoriasis	1.01e-05	8.01e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL6—psoriasis	1e-05	7.94e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CXCL8—psoriasis	9.99e-06	7.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—IL6—psoriasis	9.96e-06	7.88e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—APOE—psoriasis	9.91e-06	7.84e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—JUN—psoriasis	9.85e-06	7.79e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NFKB1—psoriasis	9.84e-06	7.78e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IFNG—psoriasis	9.81e-06	7.76e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.79e-06	7.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—TYK2—psoriasis	9.67e-06	7.65e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NFKB1—psoriasis	9.48e-06	7.5e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD4—psoriasis	9.48e-06	7.49e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL6—psoriasis	9.21e-06	7.28e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CAT—psoriasis	9.14e-06	7.23e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—psoriasis	8.93e-06	7.06e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—LEP—psoriasis	8.88e-06	7.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APOE—psoriasis	8.88e-06	7.02e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—STAT3—psoriasis	8.84e-06	6.99e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCL8—psoriasis	8.82e-06	6.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IL6—psoriasis	8.8e-06	6.96e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CD4—psoriasis	8.75e-06	6.92e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CAT—psoriasis	8.63e-06	6.83e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PPARG—psoriasis	8.63e-06	6.83e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—psoriasis	8.61e-06	6.81e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—psoriasis	8.53e-06	6.75e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—STAT3—psoriasis	8.52e-06	6.74e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—IL6—psoriasis	8.5e-06	6.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—JUN—psoriasis	8.48e-06	6.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NFKBIA—psoriasis	8.27e-06	6.54e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—JUN—psoriasis	8.2e-06	6.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NFKB1—psoriasis	8.16e-06	6.46e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—psoriasis	8.14e-06	6.44e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NFKB1—psoriasis	7.89e-06	6.24e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CAT—psoriasis	7.87e-06	6.22e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—psoriasis	7.81e-06	6.18e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—psoriasis	7.66e-06	6.06e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—STAT3—psoriasis	7.34e-06	5.8e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—psoriasis	7.17e-06	5.67e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOE—psoriasis	7.1e-06	5.62e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—psoriasis	7.09e-06	5.61e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CAT—psoriasis	7.07e-06	5.59e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CARM1—psoriasis	6.91e-06	5.46e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CAT—psoriasis	6.9e-06	5.45e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TYK2—psoriasis	6.78e-06	5.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—psoriasis	6.77e-06	5.36e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—psoriasis	6.75e-06	5.33e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOE—psoriasis	6.71e-06	5.31e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—psoriasis	6.5e-06	5.14e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CAT—psoriasis	6.5e-06	5.14e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CAT—psoriasis	6.44e-06	5.09e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARG—psoriasis	6.19e-06	4.89e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—psoriasis	6.18e-06	4.88e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—psoriasis	6.15e-06	4.86e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOE—psoriasis	6.12e-06	4.84e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—psoriasis	5.95e-06	4.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—psoriasis	5.9e-06	4.66e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARG—psoriasis	5.84e-06	4.62e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—psoriasis	5.61e-06	4.44e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOE—psoriasis	5.49e-06	4.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JUN—psoriasis	5.48e-06	4.34e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—psoriasis	5.41e-06	4.28e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOE—psoriasis	5.36e-06	4.24e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARG—psoriasis	5.33e-06	4.21e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NFKB1—psoriasis	5.28e-06	4.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—psoriasis	5.13e-06	4.05e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOE—psoriasis	5.05e-06	3.99e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOE—psoriasis	5.01e-06	3.96e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—psoriasis	4.96e-06	3.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—psoriasis	4.79e-06	3.79e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARG—psoriasis	4.78e-06	3.78e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—psoriasis	4.74e-06	3.75e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—psoriasis	4.73e-06	3.74e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARG—psoriasis	4.67e-06	3.69e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARG—psoriasis	4.4e-06	3.48e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARG—psoriasis	4.36e-06	3.45e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CAT—psoriasis	4.25e-06	3.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—psoriasis	3.62e-06	2.86e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—psoriasis	3.31e-06	2.62e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOE—psoriasis	3.3e-06	2.61e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARG—psoriasis	2.88e-06	2.27e-05	CbGpPWpGaD
